Here's Why Cencora (COR) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Here is how Cencora (COR) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Here's Why Cencora (COR) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript
Cencora, Inc. ( COR ) Q4 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Robert Mauch - President, CEO & Director James Cleary - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Michael Cherny - Leerink Partners LLC, Research Division Charles Rhyee - TD Cowen, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Allen Lutz - BofA Securities, Research Division Eric Percher - Nephron Research LLC Steven Valiquette - Mizuho Securities USA LLC, Research Division George Hill - Deutsche Bank AG, Research Division Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division Presentation Operator Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Fourth Quarter and Full Year Results Call. My name is Lucy, and I'll be coordinating your call today.
COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves
Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.
Cencora (COR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cencora (COR) Q4 Earnings and Revenues Surpass Estimates
Cencora (COR) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.79 per share. This compares to earnings of $3.34 per share a year ago.
Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain
The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.
Countdown to Cencora (COR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Cencora (COR) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
